ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...
The FDA has approved Remicade from Janssen Biotech to treat moderately to severely active ulcerative colitis in children over age 6 who responded inadequately to conventional therapy, according to an ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the subcutaneous formulation of Celltrion USA’s Zymfentra as maintenance therapy for patients ...
LAS VEGAS -- In patients with inflammatory bowel disease who lost response after infliximab (Remicade) induction, escalating the maintenance dose of the subcutaneous infliximab biosimilar CT-P13 ...
Aggressive infliximab dosing regimens – intensified induction or accelerated induction – show similar clinical responses and remission rates as the standard infliximab dosing approach in patients with ...
“For a patient with severe MES 3 disease, speed of onset is a priority, so it may be reasonable to prioritize use of upadacitinib or infliximab given their incremental efficacy with increasing ...
JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- Celltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) ...
REMICADE® (INFLIXIMAB) RECEIVES POSITIVE OPINION FROM CHMP IN EUROPE FOR TREATMENT OF ULCERATIVE COLITIS IN PEDIATRIC PATIENTS Positive Opinion Recommends Approval of the First and Only Anti-TNF ...
On October 23, 2023, Celltrion announced FDA approval for ZYMFENTRA (infliximab-dyyb), a subcutaneous formulation for maintenance therapy for patients with moderately to severely active ulcerative ...
Credit: Celltrion USA. Zymfentra is a subcutaneous formulation of Inflectra, a biosimilar to Remicade. Zymfentra is indicated as maintenance treatment only; all patients must complete an IV induction ...
LONDON, Dec 17 (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Wednesday it had recommended the use of Remicade as an option for treating acute exacerbations of ulcerative ...
Please provide your email address to receive an email when new articles are posted on . Infliximab induction and maintenance were associated with “potentially improved efficacy outcomes” vs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results